Archive for March, 2008
Shares of Merck & Co. and Schering-Plough Corp. sank Monday after heart doctors said millions of people taking the cholesterol drugs Vytorin and Zetia should switch to older, cheaper drugs that work as well. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Merck & Co. Inc. today saw the largest daily drop in its stock value since the pain reliever Vioxx was withdrawn in the fall of 2004. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
March 31 (Bloomberg) — Merck & Co. and Schering-Plough Corp. sank in New York trading after heart doctors said millions of people taking the cholesterol pills Vytorin and Zetia should switch to older, cheaper drugs that work as well. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
March 31 (Bloomberg) — Schering-Plough Corp. and Merck & Co. sank in New York trading after heart doctors said millions of people taking the cholesterol pills Vytorin and Zetia should instead be using older, cheaper drugs proven to lower risks. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Merck’s and Schering-Plough’s anti-cholesterol drug Vytorin Pharmaceuticals, shows their cholesterol drug Vytorin, produced in conjunction with Merck & Co. The FDA approved Vytorin 23 July 2004. According to Schering-Plough and Merck, Vytorin is the only drug that treats both means the body has of raising low-density Lipoprotein (LDL) cholesterol levels. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
New clinical trials have increased doubts about the efficiency of Merck and Schering-Plough’s prized anti-cholesterol drug Vytorin and its ability to fight cardiovascular disease, according to medical data released here. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Good news for AstraZeneca’s cholesterol pill Crestor is bad news for the makers of Zetia and Vytorin. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
New data about the controversial cholesterol fighter Vytorin failed to quell concerns that the drug might not be as good as thought at keeping heart disease at bay, leading an expert panel to recommend on Sunday that patients stick with statins. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx |
|